Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients

Launched by THE UNIVERSITY OF HONG KONG · Apr 30, 2015

Keywords

ClinConnect Summary

This clinical trial is studying new tests, called biomarkers, that could help predict if patients with severe liver disease (known as cirrhosis) will develop a serious condition called hepatorenal syndrome, which affects the kidneys. Researchers are looking at different substances found in the blood and urine of patients to see if they can tell who might be at risk for this condition. The trial is currently recruiting participants who have advanced cirrhosis and are being considered for a liver transplant.

To be eligible for the study, patients must have advanced cirrhosis (classified as Child's B or C) and be willing to give their consent to participate. However, those with other kidney diseases cannot join. Participants will provide samples of their blood and urine, which will be compared between those who develop hepatorenal syndrome and those who do not. This research aims to improve early detection and treatment for patients facing this serious complication of liver disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with advanced cirrhosis (Child's B or C) referred for liver transplantation
• • Willing to give informed consent
• Exclusion Criteria:
• • Patients with co-existing renal diseases